
USD
+$0.00
(+0.00%
)At Close (As of Oct 24, 2025)
$1.92B
Market Cap
-
P/E Ratio
-1.44
EPS
$55.33
52 Week High
$24.07
52 Week Low
HEALTHCARE
Sector
| Field | Value (USD) |
|---|---|
| Gross Profit | $133M |
| Total Revenue | $313M |
| Cost Of Revenue | $180M |
| Costof Goods And Services Sold | $180M |
| Operating Income | -$221M |
| Selling General And Administrative | $218M |
| Research And Development | $91M |
| Operating Expenses | $354M |
| Investment Income Net | - |
| Net Interest Income | $15M |
| Interest Income | $15M |
| Interest Expense | $29K |
| Non Interest Income | - |
| Other Non Operating Income | - |
| Depreciation | - |
| Depreciation And Amortization | $31M |
| Income Before Tax | -$208M |
| Income Tax Expense | $560K |
| Interest And Debt Expense | - |
| Net Income From Continuing Operations | -$209M |
| Comprehensive Income Net Of Tax | - |
| Ebit | -$208M |
| Ebitda | -$177M |
| Net Income | -$209M |
| Field | Value (USD) |
|---|---|
| Total Assets | $614M |
| Total Current Assets | $347M |
| Cash And Cash Equivalents At Carrying Value | $226M |
| Cash And Short Term Investments | $226M |
| Inventory | $24M |
| Current Net Receivables | $35M |
| Total Non Current Assets | $268M |
| Property Plant Equipment | - |
| Accumulated Depreciation Amortization Ppe | - |
| Intangible Assets | $14M |
| Intangible Assets Excluding Goodwill | $14M |
| Goodwill | $86M |
| Investments | - |
| Long Term Investments | - |
| Short Term Investments | $50M |
| Other Current Assets | $11M |
| Other Non Current Assets | - |
| Total Liabilities | $142M |
| Total Current Liabilities | $71M |
| Current Accounts Payable | $1.6M |
| Deferred Revenue | - |
| Current Debt | - |
| Short Term Debt | $15M |
| Total Non Current Liabilities | $71M |
| Capital Lease Obligations | $85M |
| Long Term Debt | - |
| Current Long Term Debt | - |
| Long Term Debt Noncurrent | - |
| Short Long Term Debt Total | $85M |
| Other Current Liabilities | $35M |
| Other Non Current Liabilities | $407K |
| Total Shareholder Equity | $473M |
| Treasury Stock | - |
| Retained Earnings | -$1.2B |
| Common Stock | - |
| Common Stock Shares Outstanding | $58M |
| Field | Value (USD) |
|---|---|
| Operating Cashflow | -$64M |
| Payments For Operating Activities | - |
| Proceeds From Operating Activities | - |
| Change In Operating Liabilities | - |
| Change In Operating Assets | - |
| Depreciation Depletion And Amortization | $31M |
| Capital Expenditures | $5.1M |
| Change In Receivables | - |
| Change In Inventory | $8M |
| Profit Loss | - |
| Cashflow From Investment | -$3.1M |
| Cashflow From Financing | $6.9M |
| Proceeds From Repayments Of Short Term Debt | - |
| Payments For Repurchase Of Common Stock | - |
| Payments For Repurchase Of Equity | - |
| Payments For Repurchase Of Preferred Stock | - |
| Dividend Payout | - |
| Dividend Payout Common Stock | - |
| Dividend Payout Preferred Stock | - |
| Proceeds From Issuance Of Common Stock | - |
| Proceeds From Issuance Of Long Term Debt And Capital Securities Net | - |
| Proceeds From Issuance Of Preferred Stock | - |
| Proceeds From Repurchase Of Equity | -$4M |
| Proceeds From Sale Of Treasury Stock | - |
| Change In Cash And Cash Equivalents | - |
| Change In Exchange Rate | - |
| Net Income | -$209M |
| Field | Value (USD) |
|---|---|
| Gross Profit | $133M |
| Total Revenue | $313M |
| Cost Of Revenue | $180M |
| Costof Goods And Services Sold | $180M |
| Operating Income | -$221M |
| Selling General And Administrative | $218M |
| Research And Development | $91M |
| Operating Expenses | $354M |
| Investment Income Net | - |
| Net Interest Income | $15M |
| Interest Income | $15M |
| Interest Expense | $29K |
| Non Interest Income | - |
| Other Non Operating Income | - |
| Depreciation | - |
| Depreciation And Amortization | $31M |
| Income Before Tax | -$208M |
| Income Tax Expense | $560K |
| Interest And Debt Expense | - |
| Net Income From Continuing Operations | -$209M |
| Comprehensive Income Net Of Tax | - |
| Ebit | -$208M |
| Ebitda | -$177M |
| Net Income | -$209M |
Sector: HEALTHCARE
Industry: DIAGNOSTICS & RESEARCH
Twist Bioscience Corporation (TWST) is a prominent player in the synthetic biology sector, focused on the design and manufacture of high-quality synthetic DNA products for applications spanning pharmaceuticals, agriculture, and industrial biotechnology. Based in South San Francisco, California, the company utilizes its proprietary DNA synthesis technology to provide scalable, cost-effective solutions that meet the growing demands of its diverse clientele. With a commitment to innovation and excellence, Twist is strategically positioned to lead advancement in genetic discovery and applications, reinforcing its critical role in the rapidly evolving landscape of synthetic biology.